Yu L, Guo W-C, Zhao S-H, Tang J, Chen J-L. Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. APMIS 2010; 118: 222–29.

Osteosarcoma is the most common primary malignancy of bone. Overexpression of mitotic arrest defective protein 2 (MAD2) is found in many human neoplasms, but its role in the oncogenesis of osteosarcoma is an untouched topic. The objective of this research was to observe the expression of MAD2 in human osteosarcoma and explore its clinicopathologic significance. MAD2 expression was analyzed in 48 primary osteosarcoma cases (19 osteoblastic osteosarcomas, 17 chondroblastic osteosarcomas and 12 fibroblastic osteosarcomas) using immunohistochemistry. A total of 20 normal bone specimens formed a control group. MAD2 was commonly overexpressed in human osteosarcoma. Immunopositivity was higher in tumors with lower differentiation and higher clinical stage. Increased expression of MAD2 was associated with earlier metastasis and poorer survival. Our findings provide evidence that MAD2 contributes to the pathogenesis and development of human osteosarcoma, Testing may have a clinical role in predicting prognosis, selecting appropriate chemotherapeutic strategies and providing novel strategies for osteosarcoma therapy.

References

1 Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005; 7: 967–76.
10.1593/neo.05394
CAS PubMed Web of Science® Google Scholar
2 Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643–9.
10.1038/25292
CAS PubMed Web of Science® Google Scholar
3 Bridge JA, Nelson M, McComb E, McGuire MH, Rosenthal H, Vergara G, et al. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genet Cytogenet 1997; 95: 74–87.
10.1016/S0165-4608(96)00306-8
CAS PubMed Web of Science® Google Scholar
4 Murata H, Kusuzaki K, Hirasawa Y, Ashihara T, Abe T, Inazawa J. Relationship between chromosomal aberrations by fluorescence in situ hybridization and DNA ploidy by cytofluorometry in osteosarcoma. Cancer Lett 1999; 139: 221–6.
10.1016/S0304-3835(99)00042-7
CAS PubMed Web of Science® Google Scholar
5 Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K, et al. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 2003; 36: 7–16.
10.1002/gcc.10132
CAS PubMed Web of Science® Google Scholar
6 Bharadwaj R, Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 2004; 23: 2016–27.
10.1038/sj.onc.1207374
CAS PubMed Web of Science® Google Scholar
7 Tanaka K, Nishioka J, Kato K, Nakamura A, Mouri T, Miki C, et al. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res 2001; 92: 952–8.
10.1111/j.1349-7006.2001.tb01186.x
CAS PubMed Web of Science® Google Scholar
8 Rimkus C, Friederichs J, Rosenberg R, Holzmann B, Siewert JR, Janssen KP. Expression of the mitotic checkpoint gene MAD2L2 has prognostic significance in colon cancer. Int J Cancer 2007; 120: 207–11.
10.1002/ijc.22155
CAS PubMed Web of Science® Google Scholar
9 Zhang SH, Xu AM, Chen XF, Li DH, Sun MP, Wang YJ. Clinicopathologic significance of mitotic arrest defective protein 2 overexpression in hepatocellular carcinoma. Hum Pathol 2008; 39: 1827–34.
10.1016/j.humpath.2008.06.003
CAS PubMed Web of Science® Google Scholar
10 Imai Y, Shiratori Y, Kato N, Inoue T, Omata M. Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1 is rare in sporadic digestive tract cancers. Jpn J Cancer Res 1999; 90: 837–40.
10.1111/j.1349-7006.1999.tb00824.x
CAS PubMed Web of Science® Google Scholar
11 Hernando E, Orlow I, Liberal V, Nohales G, Benezra R, Cordon-Cardo C. Molecular analyses of the mitotic checkpoint components hsMAD2, hBUB1 and hBUB3 in human cancer. Int J Cancer 2001; 95: 223–7.
10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L
CAS PubMed Web of Science® Google Scholar
12 Ruddy DA, Gorbatcheva B, Yarbrough G, Schlegel R, Monahan JE. No somatic mutations detected in the Mad2 gene in 658 human tumors. Mutat Res 2008; 641: 61–3.
10.1016/j.mrfmmm.2008.02.008
CAS PubMed Web of Science® Google Scholar
13 Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, et al. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Oncogene 1999; 18: 4295–300.
10.1038/sj.onc.1202807
CAS PubMed Web of Science® Google Scholar
14 Nomoto S, Haruki N, Takahashi T, Masuda A, Koshikawa T, Takahashi T, et al. Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers. Oncogene 1999; 18: 7180–3.
10.1038/sj.onc.1203141
CAS PubMed Web of Science® Google Scholar
15 Percy MJ, Myrie KA, Neeley CK, Azim JN, Ethier SP, Petty EM. Expression and mutational analyses of the human MAD2L1gene in breast cancer cells. Genes Chromosomes Cancer 2000; 29: 356–62.
10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N
CAS PubMed Web of Science® Google Scholar
16 Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430: 797–802.
10.1038/nature02820
CAS PubMed Web of Science® Google Scholar
17 Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153: 106–20.
10.1097/00003086-198011000-00013
Google Scholar
18 Wang LL. Biology of osteogenic sarcoma. Cancer J 2005; 11: 294–305.
10.1097/00130404-200507000-00005
CAS PubMed Web of Science® Google Scholar
19 Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007; 26: 1–18.
10.1089/dna.2006.0505
CAS PubMed Web of Science® Google Scholar
20 Sotillo R, Hernando E, Díaz-Rodríguez E, Teruya-Feldstein J, Cordón-Cardo C, Lowe SW, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007; 11: 9–23.
10.1016/j.ccr.2006.10.019
CAS PubMed Web of Science® Google Scholar
21 Shi Q, King RW. Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 2005; 437: 1038–42.
10.1038/nature03958
CAS PubMed Web of Science® Google Scholar
22 Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci USA 2004; 101: 8699–704.
10.1073/pnas.0401142101
CAS PubMed Web of Science® Google Scholar
23 Dorer RK, Zhong S, Tallarico JA, Wong WH, Mitchison TJ, Murray AW. A small-molecule inhibitor of Mps1 blocks the spindle-checkpoint response to a lack of tension on mitotic chromosomes. Curr Biol 2005; 15: 1070–6.
10.1016/j.cub.2005.05.020
CAS PubMed Web of Science® Google Scholar
24 Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994; 12: 423–31.
10.1200/JCO.1994.12.2.423
CAS PubMed Web of Science® Google Scholar
25 Sudo T, Nitta M, Saya H, Ueno NT. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004; 64: 2502–8.
10.1158/0008-5472.CAN-03-2013
CAS PubMed Web of Science® Google Scholar
26 Du Y, Yin F, Liu C, Hu S, Wang J, Xie H, et al. Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway. Biochem Biophys Res Commun 2006; 345: 1092–8.
10.1016/j.bbrc.2006.04.172
CAS PubMed Web of Science® Google Scholar
27 Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316: 1160–6.
10.1126/science.1140321
CAS PubMed Web of Science® Google Scholar
28 Luu HH, Zhou L, Haydon RC, Deyrup AT, Montag AG, Huo D, et al. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett 2005; 229: 135–48.
10.1016/j.canlet.2005.02.015
CAS PubMed Web of Science® Google Scholar
29 Wang X, Jin DY, Wong YC, Cheung AL, Chun AC, Lo AK, et al. Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells. Carcinogenesis 2000; 21: 2293–7.
10.1093/carcin/21.12.2293
CAS PubMed Web of Science® Google Scholar
30 Wang X, Jin DY, Ng RW, Feng H, Wong YC, Cheung AL, et al. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res 2002; 62: 1662–8.
CAS PubMed Web of Science® Google Scholar
31 Jeong SJ, Shin HJ, Kim SJ, Ha GH, Cho BI, Baek KH, et al. Transcriptional abnormality of the hsMAD2 mitotic checkpoint gene is a potential link to hepatocellular carcinogenesis. Cancer Res 2004; 64: 8666–73.
10.1158/0008-5472.CAN-03-3455
CAS PubMed Web of Science® Google Scholar
32 Michel LS, Liberal V, Chatterjee A, Kirchwegger R, Pasche B, Gerald W, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001; 409: 355–9.
10.1038/35053094
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume118, Issue3

March 2010

Pages 222-229

Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma

Abstract

References

Citing Literature

References

Related

Information